Elevation Oncology, Inc. (Nasdaq: ELEV), a US-based innovative oncology company, announced on Monday that it has named Darcy Mootz, PhD as its new director.

Dr Mootz, an experienced life sciences executive, has expertise across corporate strategy, corporate development, finance, and operations.

Presently, Mootz serves as president of Architect Therapeutics. She has earlier served as head of Amunix Pharmaceuticals and chief business officer of Amunix. She has served as an independent consultant working with venture capital firms and life sciences companies on corporate development and strategy projects. She has held the position of chief business officer of ORIC Pharmaceuticals and vice president, Corporate Development at Achaogen. She also serves on the board of directors of Alpha-9 Oncology.

Steve Elms, managing partner of Aisling Capital and chairman of Elevation Oncology, said, 'We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development strategies, advancing products towards approval and launching new medicines for the treatment of cancer. In addition, her broad expertise complements the strengths and skills of Elevation Oncology's board of directors, and I am confident she will provide important perspective as we continue to advance EO-3021 through clinical development. We look forward to Darcy's many contributions.'